

HTA[®] System *In-Office* Procedure

Expand Your Options for Endometrial Ablation

As physicians, you know that patient tolerability and consistent clinical outcomes are what matters. The ability to perform the HTA System procedure in an In-Office environment may provide benefits for both you and your patient ... the comfort your patients desire, and the clinical results you demand.

- **Consistent Clinical Outcomes**
- **Tolerability** - *Paracervical Block with Oral Sedation*
- **Versatility**

**Boston
Scientific**
Delivering what's next.™



Her idea of
patient comfort.

HTA® System *In-Office* Procedure

Expand Your Options for Endometrial Ablation

Consistent Clinical Outcomes

The HTA® System has the highest FDA Phase III clinical amenorrhea rates at three years vs Novasure®, ThermaChoice®, and Her Option® Systems (per protocol patients).^{1,2}

- 53% Amenorrhea & 94% Success Rate @ 3 year follow-up of FDA Trial per protocol (72/136).²

Tolerability - *Paracervical Block with Oral Sedation*

- No reports of procedures discontinued for pain, in one study involving 285 patients.³
- Average peak pain score was 3.6 on a scale of 1-10 in-office following a prospective and retrospective review of 55 survey respondents of a total of 76 patients.⁴

Versatility

The HTA System may have the ability to treat various irregular cavities. Potentially more patients may be able to receive treatment than our competitors (Novasure, ThermaChoice, and Her Option Systems).¹

- Result – more potential office revenue.



For more information on
the HTA System, please call
1.888.272.1001

1. Technology Comparison, MVU 6270, HTA System In-Office Global Endometrial Ablation

2. Goldrath MH. Evaluation of HydroThermAblator and Rollerball Endometrial Ablation for Menorrhagia 3 years after Treatment. Journal of the American Association of Gynecologic Laparoscopists. 2003;10(4):505-511

3. Glasser MH. Perioperative Pain Management and Why it Works. Presented at AAGL. 11-2006

4. Philips R. Practical In-office Experience with the HTA System. Poster Presentation as AAGL 11-2006

Refer to the HTA System User's Manual provided with product for complete instructions for use. INDICATIONS: The HTA System is a hysteroscopic thermal ablation device intended to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia (excessive uterine bleeding) due to benign causes for whom childbearing is complete. **CONTRAINDICATIONS:** The HTA System is contraindicated for use in a patient: who is pregnant or wants to be pregnant in the future, as pregnancy after ablation can be dangerous to both mother and fetus; who has known or suspected endometrial carcinoma or premalignant change of the endometrium, such as adenomatous hyperplasia; who has active pelvic inflammatory disease or pyosalpinx; hydrosalpinx; who has any anatomical or pathologic condition in which weakness of the myometrium could exist, such as, prior classic cesarean section or transmural myomectomy; who has an intrauterine device in place; or who has active genital or urinary tract infection, e.g., cervicitis, endometritis, vaginitis, cystitis, etc., at the time of treatment. **POTENTIAL ADVERSE EFFECTS** that may occur include: thermal injury to adjacent tissue including cervix, vagina, vulva, and/or perineum; heated saline escaping from the device system into the vascular spaces; hemorrhage; perforation of uterus; complications with pregnancy (Note: pregnancy following ablation is dangerous to both the mother and the fetus); risks associated with hysteroscopy. **WARNINGS:** NOTE: Failure to follow any instructions or to heed any Warnings or Precautions could result in serious patient injury. **CAUTION: Federal Law (USA) restricts this device to sale by or on the order of a physician. The physician using the device must be trained in diagnostic hysteroscopy.**

Boston Scientific

Delivering what's next.™

Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537
www.bostonscientific.com/gynecology

Ordering Information
1.888.272.1001

© 2007 Boston Scientific Corporation
or its affiliates. All rights reserved.

MVU6480 5M 4/07-4/09